| Wednesday, August 15thPatient information seminars in Stockholm (11.9.2018) and in Helsinki (4.10.2018)
READ MORE
EPDA | Thursday, January 18thParkinson’s prevalence expected to increase by 18% by 2025
Read More
Herantis Pharma | Wednesday, September 27thPatient recruitment started and first patient consented in the CDNF Phase I-II clinical study
Read more
TreatER | Friday, June 30thTreatER Horizon 2020 program website launched
EPDA | Wednesday, May 24thHow wearable devices can help people with Parkinson’s communicate better with their doctors
Read More
EPDA | Thursday, April 13th200 years of Parkinson’s disease: still no cure, but EU policy must drive improvements in quality of life
Read more
EPDA | Tuesday, April 11thWorld Parkinson’s Day: #Unite for Parkinsons social media campaign
Read more
Herantis Pharma | Thursday, March 23rdHerantis Pharma’s clinical study with CDNF in Parkinson’s disease authorized in Sweden
Read more
Herantis Pharma | Monday, December 12thHerantis Pharma’s Parkinson study wins EUR 6.0 million grant from the European Union Horizon 2020 program
Read more